Publications by authors named "T de Haro"

This study aimed to investigate the effects 24 weeks of supervised exercise training at different intensities on S-Klotho and 25-hydroxyvitamin D plasma levels in young adults. This report was based on a secondary analysis from the ACTIBATE single-center unblinded randomized controlled trial (ClinicalTrials.gov ID: NCT02365129).

View Article and Find Full Text PDF

Nuak1 (NUAK family SnF1-like kinase-1) is a serine-threonine kinase and a member of the AMPK family. Interest in Nuak1 has increased over the years due to the role it plays in several biological processes, from tumor cell invasion and proliferation to Tau stabilization. Nuak1 is expressed in many cancer cell lines and many reports describe this target as an oncogene, the inhibition of which is hypothesized to be valuable for treating various cancer types including glioma.

View Article and Find Full Text PDF
Article Synopsis
  • High off-target promiscuity and potent cytotoxicity in drug development can lead to a high failure rate, making safety assessment critical for compounds like novel plasmepsin X (PMX) inhibitors for malaria treatment.
  • A total of 249 PMX compounds were tested through various assays, revealing a correlation between high cytotoxicity in liver cells and poor tolerability in animal studies, often associated with specific receptor activities.
  • A structured approach using in vitro assays is necessary to identify harmful targets early and improve the chances of selecting safer compounds for further testing.
View Article and Find Full Text PDF

Quinoline-related antimalarial drugs have been associated with cardiotoxicity risk, in particular QT prolongation and QRS complex widening. In collaboration with Medicines for Malaria Venture, we discovered novel plasmepsin X (PMX) inhibitors for malaria treatment. The first lead compounds tested in anesthetized guinea pigs (GPs) induced profound QRS widening, although exhibiting weak inhibition of NaV1.

View Article and Find Full Text PDF